Geographic Atrophy Clinical Trial
Official title:
A Phase 2 Multi-Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Patients with advanced dry AMD with GA meeting inclusion criteria will be randomized in one eye in a 1:1:1 ratio comparing intravitreal high or low dose AAVCAGsCD59 with a sham injection. All enrolled subjects will be followed for 24 months to evaluate reduction in GA growth and safety of intravitreal AAVCAGsCD59.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06161584 -
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
||
| Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
| Completed |
NCT02515942 -
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
|
Phase 2 | |
| Completed |
NCT02503332 -
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
|
Phase 2 | |
| Recruiting |
NCT04339764 -
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT03295877 -
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 1 | |
| Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00973011 -
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
|
Phase 1 | |
| Terminated |
NCT02247479 -
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
Phase 3 | |
| Active, not recruiting |
NCT06006585 -
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
|
Phase 1 | |
| Recruiting |
NCT05961332 -
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy
|
N/A | |
| Terminated |
NCT02247531 -
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
Phase 3 | |
| Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
| Completed |
NCT01002950 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
|
Phase 2 | |
| Completed |
NCT03777332 -
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
|
Phase 1 | |
| Active, not recruiting |
NCT04676854 -
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
|
N/A | |
| Recruiting |
NCT02372916 -
Geographic Atrophy and Intravitreal Ranibizumab Injections
|
N/A | |
| Active, not recruiting |
NCT05380492 -
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Terminated |
NCT04607148 -
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
Phase 2 | |
| Terminated |
NCT02087085 -
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
|
Phase 2 |